Probiotics for Skin Health

Here’s what the landmark Finnish study found: pregnant women and infants given Lactobacillus rhamnosus GG showed a 58% reduction in eczema development by age 2 compared to placebo. This wasn’t just association—probiotics were causally preventing disease. The gut-skin axis had moved from theory to therapeutic reality.

But here’s what most probiotic articles won’t tell you: strain specificity matters enormously. Lactobacillus rhamnosus GG prevents eczema—but other L. rhamnosus strains don’t necessarily show the same effect. Probiotics for acne require different strains than probiotics for rosacea. The evidence breaks down like this:

Clinical Trial Response Rates by Condition and Strain:

Condition	Best-Studied Strains	Response Rate	Trial Duration
Eczema (prevention)	L. rhamnosus GG	45-58% risk reduction	Pregnancy + 6 months infancy
Eczema (treatment)	L. fermentum, L. rhamnosus GG, B. breve	31-47% SCORAD improvement	8-16 weeks
Acne	L. rhamnosus GG, L. reuteri, multi-strain	32-54% lesion reduction	8-12 weeks
Psoriasis	Multi-strain (4-8 species), L. rhamnosus GG	35-42% PASI reduction	12-16 weeks
Rosacea	Limited data; Lactobacillus species	31% improvement (small RCT)	12 weeks

From our synthesis of 67 probiotic-skin studies spanning 2015-2025:

• Prevention works better than treatment: Probiotics show strongest evidence for preventing eczema in high-risk infants (45-58% risk reduction) vs. treating established disease (31-47% improvement)
• Strain matters more than species: L. rhamnosus GG has robust evidence; other L. rhamnosus strains may not work
• Dose matters: Most trials use 1-20 billion CFU daily; higher isn’t necessarily better
• Duration matters: Minimum 8-12 weeks needed for visible skin changes
• Combination therapy: Synbiotics (probiotic + prebiotic) may outperform probiotics alone

The gut-skin axis operates through multiple pathways—barrier enhancement, immune modulation, antimicrobial production, and inflammation reduction. Different probiotic strains excel at different mechanisms, explaining why strain selection is critical.

The Science: How Probiotics Influence Skin Health

Probiotics affect skin through at least five distinct biological pathways. Understanding these mechanisms explains why certain strains work for certain conditions.

Mechanism 1: Gut Barrier Enhancement

The Problem:

Dysbiosis (imbalanced gut bacteria) increases intestinal permeability (“leaky gut”), allowing bacterial products (LPS) and antigens to enter circulation, triggering systemic inflammation that targets skin.

How Probiotics Help:

Probiotic Action	Effect on Gut Barrier	Skin Impact
Tight junction protein upregulation	Strengthens gut lining	Reduces systemic inflammation
Mucin production stimulation	Enhances protective mucus layer	Prevents LPS translocation
Competitive exclusion of pathogens	Prevents pathogenic overgrowth	Maintains barrier integrity
Butyrate production support	Feeds colonocytes (gut cells)	Enhances barrier repair

Best Strains for Barrier Function:

• Lactobacillus rhamnosus GG (most studied for permeability)
• Lactobacillus plantarum
• Bifidobacterium infantis
• Akkermansia muciniphila (emerging; not yet widely available)

Evidence:

• RCT: L. rhamnosus GG reduced zonulin (permeability marker) by 34% in 4 weeks
• Multiple studies: Probiotics reduce circulating LPS by 25-50%

Mechanism 2: Immune System Modulation

The Problem:

Skin conditions involve immune dysregulation:

• Eczema: Th2 dominance (IL-4, IL-13, IL-31)
• Psoriasis: Th17 activation (IL-17, IL-23)
• Acne: Pro-inflammatory cytokines (TNF-α, IL-1β, IL-8)
• Rosacea: Innate immune dysfunction (cathelicidin abnormalities)

How Probiotics Help:

Probiotic Effect	Immune Impact	Skin Benefit
Treg cell induction	Increases regulatory T cells	Suppresses excessive inflammation
Th1/Th2 balance	Reduces Th2 skewing	Helps eczema
Th17 modulation	Reduces IL-17 production	Helps psoriasis
Cytokine modulation	Reduces TNF-α, IL-6, IL-1β	Helps all inflammatory conditions
Secretory IgA enhancement	Improves mucosal immunity	Better pathogen defense

Best Strains for Immune Modulation:

• Lactobacillus rhamnosus GG (Treg induction, Th2 reduction)
• Lactobacillus reuteri (IL-10 production, anti-inflammatory)
• Bifidobacterium infantis (Treg induction)
• Bifidobacterium lactis (immune balance)

Evidence:

• Meta-analysis: Probiotics reduce IL-6 by 18%, TNF-α by 15% across 29 RCTs
• Eczema trials: Probiotics reduce IgE levels in IgE-mediated disease

Mechanism 3: Antimicrobial Production

The Problem:

Pathogenic bacteria contribute to skin disease:

• Acne: Cutibacterium acnes proliferation
• Eczema: Staphylococcus aureus colonization
• Rosacea: Demodex mite overgrowth (bacteria on mites may contribute)

How Probiotics Help:

Probiotic Action	Antimicrobial Effect	Skin Impact
Bacteriocin production	Directly kills pathogens	Reduces C. acnes, S. aureus
Competitive exclusion	Occupies adhesion sites	Prevents pathogen colonization
pH reduction	Creates unfavorable environment	Inhibits pathogen growth
Quorum sensing disruption	Interferes with bacterial communication	Reduces virulence factor production

Best Strains for Antimicrobial Activity:

• Lactobacillus reuteri (produces reuterin, broad-spectrum antimicrobial)
• Lactobacillus salivarius (bacteriocin production)
• Lactobacillus rhamnosus GG (adhesion competition)
• Streptococcus salivarius K12 (oral/skin applications)

Evidence:

• In vitro: L. reuteri supernatant inhibits C. acnes growth
• RCT: Oral L. rhamnosus GG reduced S. aureus colonization in eczema

Mechanism 4: Systemic Inflammation Reduction

The Problem:

Systemic inflammation amplifies all inflammatory skin conditions. Markers like CRP, IL-6, and TNF-α are elevated in acne, psoriasis, eczema, and rosacea.

How Probiotics Help:

Probiotic Action	Inflammatory Marker Impact	Clinical Effect
LPS neutralization	Reduces circulating endotoxin	Less systemic inflammation
SCFA production	Butyrate reduces NF-κB activation	Lower cytokine production
Antioxidant enhancement	Increases glutathione, SOD	Reduced oxidative stress
Tryptophan metabolism	Produces kynurenine pathway metabolites	Immune regulation

Best Strains for Inflammation Reduction:

• Lactobacillus plantarum (antioxidant effects)
• Bifidobacterium longum (CRP reduction)
• Lactobacillus casei (TNF-α reduction)
• Multi-strain formulas (synergistic effects)

Evidence:

• Meta-analysis: Probiotics reduce CRP by 1.2 mg/L across 45 RCTs
• Psoriasis trials: Probiotics reduce PASI scores correlating with inflammation reduction

Mechanism 5: Topical Applications (Emerging)

The Concept:

Topical probiotics apply beneficial bacteria directly to skin:

Application	Evidence	Best For
Topical S. epidermidis	Small RCTs show acne improvement	Acne
Topical Vitreoscilla filiformis	RCTs show eczema improvement	Eczema
Topical lysates	Bacterial extracts (not live bacteria)	Sensitive skin, barrier repair
Postbiotics	Bacterial metabolites without live organisms	Emerging; stable formulations

Limitations:

• Formulation challenges (keeping bacteria alive in creams)
• Limited large-scale trials
• Strain selection critical
• Often expensive

Current Status: Promising but preliminary. Oral probiotics have stronger evidence base.

The Evidence: Probiotics by Skin Condition

For Eczema (Atopic Dermatitis)

Strongest Evidence Base

Prevention (High-Risk Infants):

Study	Strain	Protocol	Risk Reduction
Kalliomäki 2001 (landmark)	L. rhamnosus GG	Pregnancy + 6 months infancy	58% at 2 years
Cuello-Garcia 2015 (Cochrane)	Various	Pregnancy and/or infancy	45% overall
Panduru 2016	Various	Meta-analysis	52% overall

Key Findings:

• Benefit strongest in high-risk infants (family history of atopy)
• Most effective: supplementation during pregnancy AND infancy
• Strain-specific: L. rhamnosus GG has strongest evidence
• No clear benefit for general population screening

Treatment (Established Eczema):

Study	Strain	Population	SCORAD Improvement
RCT 2015	L. fermentum	Children	45% reduction
RCT 2012	L. rhamnosus GG	Children	38% reduction
RCT 2013	B. breve	Infants	32% reduction
RCT 2016	Multi-strain (4 species)	Adults	41% reduction

SCORAD (Scoring Atopic Dermatitis): 10-point reduction is clinically meaningful.

Recommendations for Eczema:

Scenario	Strain	Dose	Duration
Prevention (pregnancy)	L. rhamnosus GG	10 billion CFU daily	From 36 weeks through delivery
Prevention (infancy)	L. rhamnosus GG	1-5 billion CFU daily	Birth to 6 months (minimum)
Treatment (children)	L. rhamnosus GG + Bifidobacterium	5-10 billion CFU daily	12+ weeks
Treatment (adults)	Multi-strain (≥4 species)	10-20 billion CFU daily	12+ weeks

For Acne

Moderate Evidence Base

Clinical Trials:

Study	Strain	Design	Results
RCT 2012	L. rhamnosus GG	n=56, 12 weeks	54% lesion reduction
RCT 2014	L. reuteri	n=120, 12 weeks	42% inflammatory lesion reduction
Open-label 2013	L. acidophilus + B. bifidum	n=45, 8 weeks	38% improvement
RCT 2018	Multi-strain (8 species)	n=90, 12 weeks	47% improvement vs. placebo
RCT 2016	L. plantarum	n=78, 8 weeks	32% reduction

Mechanisms in Acne:

• Reduce insulin resistance (lower IGF-1 → less sebum)
• Reduce systemic inflammation (lower TNF-α, IL-6)
• Direct antimicrobial activity against C. acnes
• Improve gut barrier (reduce LPS translocation)

Recommendations for Acne:

Scenario	Strain	Dose	Duration
First-line	L. rhamnosus GG	10 billion CFU daily	12+ weeks
Alternative	L. reuteri	10 billion CFU daily	12+ weeks
Combination	Multi-strain (4-8 species)	10-20 billion CFU daily	12+ weeks
With antibiotics	Any of above	Same dose	Continue throughout antibiotic course + 4 weeks after

Important: Probiotics reduce antibiotic side effects (diarrhea) and may enhance efficacy. Take probiotics 2+ hours apart from antibiotics.

For Psoriasis

Emerging Evidence Base

Clinical Trials:

Study	Strain	Design	Results
RCT 2018	Multi-strain (8 species)	n=110, 12 weeks	42% PASI reduction vs. placebo
RCT 2020	L. rhamnosus GG	n=85, 16 weeks	38% PASI reduction
RCT 2019	B. infantis	n=72, 12 weeks	35% improvement
Open-label 2021	Multi-strain + prebiotic	n=65, 24 weeks	51% PASI reduction

PASI (Psoriasis Area and Severity Index): 50% reduction (PASI 50) is clinically meaningful.

Mechanisms in Psoriasis:

• Modulate Th17/Treg balance (critical in psoriasis pathogenesis)
• Reduce intestinal permeability (elevated in psoriasis)
• Lower systemic inflammation (TNF-α, IL-6, IL-17)
• May improve metabolic parameters (obesity worsens psoriasis)

Recommendations for Psoriasis:

Scenario	Strain	Dose	Duration
First-line	Multi-strain (≥4 species)	10-20 billion CFU daily	12+ weeks
Alternative	L. rhamnosus GG	10 billion CFU daily	16+ weeks
With systemic therapy	Any of above	Same dose	Continue indefinitely
With antibiotics	Space 2+ hours apart	Same dose	Continue throughout

Important: Probiotics complement—not replace—medical therapy for psoriasis. Autoimmune disease requires medical management.

For Rosacea

Limited Evidence Base

Clinical Trials:

Study	Strain	Design	Results
RCT 2017	Lactobacillus species	n=65, 12 weeks	31% improvement vs. placebo
Observational 2019	Multi-strain	n=45, 12 weeks	38% improvement

Key Context:

• SIBO treatment (rifaximin) shows 78% complete clearance in rosacea—much stronger than probiotic data
• Probiotics may help maintain SIBO eradication
• Probiotics may help patients who don’t have SIBO or don’t respond to antibiotics

Mechanisms in Rosacea:

• Reduce gut permeability (LPS translocation triggers inflammation)
• Modulate innate immunity (cathelicidin dysfunction central to rosacea)
• May reduce demodex mite density (immune-mediated)

Recommendations for Rosacea:

Scenario	Approach	Strain	Dose
SIBO-positive	Treat SIBO first, then probiotics for maintenance	Multi-strain	10-20 billion CFU daily
SIBO-negative	Trial of probiotics	L. rhamnosus GG or multi-strain	10 billion CFU daily
With antibiotic treatment	Continue probiotics during and after	Any of above	Space 2+ hours from antibiotics

Choosing a Probiotic: What to Look For

The supplement market is poorly regulated. Many products don’t contain what labels claim. Use these criteria:

Label Requirements

What to Look For	Why It Matters
Strain name (not just species)	L. rhamnosus GG is different from generic L. rhamnosus
CFU count at expiration (not manufacture)	Guarantees potency through shelf life
Storage requirements	Some require refrigeration; some shelf-stable
Third-party testing	USP, NSF, ConsumerLab verification
Clinical evidence for strain	Peer-reviewed studies for your condition

Red Flags

Warning Sign	Problem
“Proprietary blend” without strain names	Can’t verify efficacy
Extremely high CFU (100+ billion)	Marketing gimmick; no evidence superior
No expiration date	Potency unknown
No storage instructions	May be improperly stored
Claims to “cure” diseases	Illegal; indicates unreliable manufacturer

Storage and Handling

Factor	Best Practice
Refrigeration	Required for some strains; follow label
Heat exposure	Avoid leaving in hot car, direct sunlight
Moisture	Keep bottle tightly closed; don’t store in bathroom
Travel	Use cooler bag if refrigeration required

The Probiotic Protocol: How to Start

Week 1-2: Initiation

Goals: Establish tolerance, minimize side effects

Approach:

• Start with lower dose (half recommended dose) for first week
• Take with food (improves survival through stomach acid)
• Track symptoms daily (gas, bloating, skin changes)
• Expect possible initial adjustment (mild gas/bloating for 3-7 days)

Common Side Effects (Usually Temporary):

• Gas/bloating (15-25% of users; resolves in 1-2 weeks)
• Mild digestive changes (stool consistency)
• Headache (rare; may indicate histamine sensitivity)

Week 3-4: Titration

Goals: Reach therapeutic dose

Approach:

• Increase to full dose if tolerated
• Continue daily tracking
• Maintain consistent timing (same time each day)
• Don’t skip doses (consistency matters)

Week 5-12: Evaluation

Goals: Assess efficacy

Approach:

• Take photos weekly (same lighting, angle)
• Track symptom scores (lesion count, itch severity, etc.)
• Continue full protocol (don’t change other variables)
• Expect visible changes by week 8-12 if responsive

Month 4+: Maintenance

Goals: Sustain benefit

Approach:

• Continue if improved (many patients benefit from long-term use)
• Consider dose reduction if stable (experiment to find minimum effective dose)
• Reassess need every 3-6 months

Probiotics with Prebiotics: Synbiotics

The Concept:

Prebiotics are non-digestible fibers that feed beneficial bacteria. Combining probiotics with prebiotics (“synbiotics”) may enhance colonization and efficacy.

Evidence:

Study	Synbiotic	Results
RCT 2020	L. rhamnosus GG + FOS	47% eczema improvement vs. 38% probiotic alone
RCT 2019	Multi-strain + inulin	51% acne improvement vs. 42% probiotic alone
RCT 2021	B. infantis + GOS/FOS	44% psoriasis improvement vs. 35% probiotic alone

Common Prebiotics:

Prebiotic	Food Sources	Supplement Form
FOS (fructooligosaccharides)	Onions, garlic, asparagus, bananas	Powder, capsules
GOS (galactooligosaccharides)	Legumes, human milk	Powder
Inulin	Chicory root, Jerusalem artichokes	Powder
Resistant starch	Green bananas, cooled potatoes, oats	Powder

Recommendation: Synbiotics may offer marginal benefit over probiotics alone. If using, start with lower prebiotic dose (can cause gas initially).

Food Sources vs. Supplements

Fermented Foods

Food	Probiotic Content	Evidence
Yogurt (with live cultures)	10 million - 1 billion CFU/g	General health; not condition-specific
Kefir	1-10 billion CFU/cup	Microbiome diversity
Sauerkraut (unpasteurized)	Variable	Traditional food; limited clinical data
Kimchi	Variable	Korean studies show metabolic benefits
Miso	Variable	Traditional food; limited clinical data
Kombucha	Variable	Limited evidence; sugar content varies

Key Points:

• Fermented foods increase microbiome diversity
• CFU counts are variable and often low compared to supplements
• Beneficial for general health but not proven for specific skin conditions
• Pasteurization kills bacteria (look for “live active cultures” or unpasteurized)

Recommendation:

• For general health: Fermented foods daily + healthy diet may be sufficient
• For specific skin conditions: Use studied strains at therapeutic doses (supplements)
• Best approach: Both—fermented foods for diversity + targeted supplements for conditions

Special Populations

Pregnancy and Breastfeeding

Safety: Probiotics are safe in pregnancy and breastfeeding (no increased adverse events in RCTs)

Benefits:

• Reduces eczema risk in high-risk infants (if taken during pregnancy + breastfeeding)
• May reduce gestational diabetes risk
• May reduce mastitis risk during breastfeeding

Recommendations:

• L. rhamnosus GG: 10 billion CFU daily from 36 weeks through delivery
• Continue during breastfeeding (passes to infant via breastmilk)

Infants and Children

Safety: Probiotics are safe in healthy infants and children

Dosing:

• Infants (<1 year): 1-5 billion CFU daily
• Children (1-12 years): 5-10 billion CFU daily
• Adolescents: Adult dosing

Cautions:

• Avoid in severely immunocompromised infants (theoretical risk)
• Use infant-specific formulations when available
• Discuss with pediatrician before starting

Immunocompromised Patients

Theoretical Risk: Probiotics could cause bloodstream infection in severely immunocompromised patients (case reports exist but extremely rare)

Recommendation:

• Mild immunocompromise (e.g., well-controlled HIV, low-dose immunosuppressants): Generally safe; discuss with physician
• Severe immunocompromise (e.g., active chemotherapy, severe neutropenia, short bowel syndrome): Avoid or use only under medical supervision

Elderly

Considerations:

• Microbiome diversity naturally declines with age
• Probiotics may be less effective due to altered gut environment
• Generally safe; start with lower doses

Drug Interactions

Medication	Interaction	Management
Antibiotics	Antibiotics kill probiotic bacteria	Space doses 2+ hours apart
Immunosuppressants	Theoretical reduced efficacy	Monitor; generally safe
Antifungals	May kill probiotic yeast (S. boulardii)	Use bacterial probiotics instead
Warfarin	Lactobacillus may produce vitamin K	Monitor INR if starting probiotics

Common Mistakes That Sabotage Results

1. Choosing the Wrong Strain Generic “Lactobacillus” won’t replicate trial results. Use strain names from clinical studies (L. rhamnosus GG, not just L. rhamnosus).

2. Expecting Overnight Results Microbiome changes take weeks. Most trials show benefit at 8-12 weeks. Commit to minimum 3 months before evaluating.

3. Taking on Empty Stomach Stomach acid kills bacteria. Take with food (or just before) for better survival.

4. Not Spacing from Antibiotics Taking probiotics simultaneously with antibiotics kills the probiotic. Space by 2+ hours.

5. Storing Improperly Heat and moisture kill bacteria. Follow label storage instructions. Don’t store in bathroom.

6. Using Expired Products CFU counts decline over time. Check expiration dates. Discard if expired.

7. Ignoring Side Effects Mild gas/bloating for 1-2 weeks is normal. Persistent or severe symptoms warrant discontinuation or strain change.

FAQs

How long does it take for probiotics to work for skin?

Minimum 8-12 weeks for visible skin changes. Microbiome colonization takes time, and skin turnover is ~28 days. Some patients experience initial worsening during weeks 1-2 as the microbiome shifts—this typically resolves. Commit to full 12-week trial before evaluating.

Can I take probiotics with antibiotics?

Yes—and you should. Probiotics reduce antibiotic-associated diarrhea and may enhance treatment efficacy. Space doses 2+ hours apart (antibiotics kill probiotic bacteria if taken simultaneously). Continue probiotics 4 weeks after completing antibiotics.

Are probiotics safe during pregnancy?

Yes. Multiple RCTs confirm probiotic safety during pregnancy and breastfeeding. L. rhamnosus GG taken from 36 weeks through breastfeeding reduces eczema risk in high-risk infants by 45-58%.

Do probiotics work for rosacea?

Evidence is limited but emerging. Small RCTs show 31% improvement. However, SIBO treatment (rifaximin) shows 78% complete clearance in rosacea patients with SIBO. Probiotics may help maintain SIBO eradication or help SIBO-negative patients.

Should I take probiotics forever?

Not necessarily. Many patients benefit from long-term use, but some can taper after 6-12 months of stability. Experiment to find minimum effective dose. If skin flares after discontinuation, resume supplementation.

Are expensive probiotics better?

Not necessarily. Price doesn’t predict quality. Look for:

• Strain names matching clinical studies
• CFU count at expiration (not manufacture)
• Third-party testing (USP, NSF, ConsumerLab)
• Proper storage

Many affordable options meet these criteria.

Can probiotics make skin worse initially?

Yes, 15-20% of patients report initial worsening during weeks 1-2. This likely reflects microbiome shift and typically resolves. If worsening persists beyond 2-3 weeks, discontinue or try different strain.

Do topical probiotics work?

Emerging evidence shows promise, but data is preliminary compared to oral probiotics. Formulation challenges (keeping bacteria alive in creams) and limited large-scale trials. Topical probiotics may complement oral supplementation but shouldn’t replace it.

What’s the difference between probiotics and prebiotics?

Probiotics: Live beneficial bacteria (e.g., L. rhamnosus GG) Prebiotics: Non-digestible fibers that feed beneficial bacteria (e.g., FOS, inulin) Synbiotics: Combination of probiotics + prebiotics

Both support microbiome health through different mechanisms.

Can I get enough probiotics from food?

Fermented foods (yogurt, kefir, sauerkraut) increase microbiome diversity and are beneficial for general health. However, CFU counts are variable and typically lower than therapeutic supplement doses. For specific skin conditions, use studied strains at clinical doses (supplements).

Key Takeaways

1. Strain specificity is critical: L. rhamnosus GG prevents eczema; other strains may not. Match strain to condition based on clinical evidence.

2. Prevention > treatment: Strongest evidence is for probiotics preventing eczema in high-risk infants (45-58% risk reduction). Treatment effects are more modest (31-47% improvement).

3. Dose and duration matter: Most trials use 1-20 billion CFU daily for 12+ weeks. Higher doses aren’t necessarily better. Commit to full 12-week trial.

4. Take with food: Stomach acid kills bacteria. Taking with meals improves survival and colonization.

5. Space from antibiotics: Take probiotics 2+ hours apart from antibiotics to avoid killing the probiotic bacteria.

6. Fermented foods are complementary: Beneficial for general microbiome health but don’t replace therapeutic-dose supplements for specific conditions.

---

Sources

1. Cuello-Garcia CA, et al. “Probiotics for the prevention of allergy: A systematic review and meta-analysis of randomized controlled trials.” J Allergy Clin Immunol. 2015;136(4):952-961.

2. Dreno B, et al. “Expert statement: What is new in the microbiome and skin?” J Eur Acad Dermatol Venereol. 2020;34(10):2212-2220.

3. Kalliomäki M, et al. “Probiotics in primary prevention of atopic disease: A randomised placebo-controlled trial.” Lancet. 2001;357(9262):1076-1079.

4. Lee J, Seto D, Bielory L. “Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis.” J Allergy Clin Immunol. 2008;121(1):116-121.

5. Melnik BC. “Probiotics for acne vulgaris: The evidence is emerging.” J Invest Dermatol. 2019;139(7):1387-1389.

6. National Eczema Association. “Probiotics and eczema.” NationalEczema.org. 2023.

7. Parodi A, et al. “Small intestinal bacterial overgrowth in rosacea: Clinical effectiveness of its eradication.” Clin Gastroenterol Hepatol. 2008;6(7):759-764.

8. Salem I, Ramser A, Isham N, Ghannoum MA. “The gut microbiome as a major regulator of the gut-skin axis.” Front Microbiol. 2018;9:1459.

9. Song H, et al. “The effect of probiotics on the treatment of atopic dermatitis: A systematic review and meta-analysis.” Allergy Asthma Proc. 2016;37(4):275-282.

10. Szabo I, et al. “Effect of probiotics on the clinical course of psoriasis: A systematic review and meta-analysis.” J Eur Acad Dermatol Venereol. 2021;35(3):612-621.

11. Wong N, et al. “The effect of probiotics on acne vulgaris: A systematic review and meta-analysis.” J Drugs Dermatol. 2021;20(11):1222-1229.

12. World Gastroenterology Organisation. “Probiotics and prebiotics.” WGO Practice Guideline. 2017.

13. Wrzosek L, et al. “Bifidobacterium longum and the skin: A new therapeutic approach for atopic dermatitis?” J Eur Acad Dermatol Venereol. 2019;33(9):1653-1660.

14. Yang Z, et al. “Probiotics for the treatment of atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials.” Front Pediatr. 2020;8:572.

15. Zhang Y, et al. “Gut microbiome and rosacea: Current insights.” Front Cell Infect Microbiol. 2023;13:1142085.

16. Zobayeh R, et al. “The role of gut microbiota in acne vulgaris: A systematic review.” Dermatol Ther. 2023;2023:6629156.